Spots Global Cancer Trial Database for Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC
Official Title: Phase 1b Single Arm, Open-label Trial of RYZ101 in Combination With Carboplatin + Etoposide + Atezolizumab in Subjects With Somatostatin Receptor Expressing (SSTR+) Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Study ID: NCT05595460
Conditions
Study Description
Brief Summary: This study aims to determine the safety, preliminary antitumor activity, and pharmacokinetics (PK) of RYZ101 in combination with standard of care (SoC) therapy consisting of carboplatin + etoposide + atezolizumab in untreated subjects with somatostatin receptor expressing (SSTR+) ES-SCLC.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
UCLA, Los Angeles, California, United States
UCSF, San Francisco, California, United States
Mayo Clinic, Jacksonville, Florida, United States
Orlando Health Cancer Institute, Orlando, Florida, United States
Corewell-Health BAMF Health, Grand Rapids, Michigan, United States
Profound Research LLC / MHP Radiation Oncology Institute, Troy, Michigan, United States
Mayo Clinic, Rochester, Minnesota, United States
Nebraska Cancer Specialists, Omaha, Nebraska, United States
Millennium Research and Clinical Development, Houston, Texas, United States
University of Utah Huntsman Cancer Hospital, Salt Lake City, Utah, United States
Pan American Center for Oncology Trials, LLC, San Juan, , Puerto Rico
Contact Details
Name: Denise Ferreira, MD
Affiliation: RayzeBio, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
